KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Expenses (2016 - 2025)

Supernus Pharmaceuticals has reported Operating Expenses over the past 15 years, most recently at $215.5 million for Q4 2025.

  • Quarterly Operating Expenses rose 41.08% to $215.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $781.2 million through Dec 2025, up 34.66% year-over-year, with the annual reading at $781.2 million for FY2025, 34.66% up from the prior year.
  • Operating Expenses was $215.5 million for Q4 2025 at Supernus Pharmaceuticals, down from $252.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $252.3 million in Q3 2025 and troughed at $107.2 million in Q2 2021.
  • The 5-year median for Operating Expenses is $151.6 million (2022), against an average of $154.5 million.
  • Year-over-year, Operating Expenses fell 18.52% in 2023 and then surged 87.13% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $153.0 million in 2021, then dropped by 13.05% to $133.0 million in 2022, then increased by 24.3% to $165.3 million in 2023, then fell by 7.6% to $152.8 million in 2024, then surged by 41.08% to $215.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Operating Expenses are $215.5 million (Q4 2025), $252.3 million (Q3 2025), and $153.3 million (Q2 2025).